- Proceeds will enable FogPharma to advance its first- and only-in-class direct β-catenin antagonist into clinical development to potentially address 20% or more of all cancers
- FogPhama’s proprietary Helicon™ peptides represent a new class of precision medicines that combines the targeting strength and specificity of antibodies with the cell penetration of small molecules
- Funds will also build a pipeline of additional high-impact Helicon drug candidates against biologically validated targets never before drugged, with accelerating speed and scalability
- Corey Goodman, Ph.D., of venBio Partners joins board of directors as Chairman
March 01, 2021 07:00 AM Eastern Standard Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)–FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered “undruggable”, today announced the Company’s $107 million Series C financing. The financing was led by venBio Partners, with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup. Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round
